Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of METR-NK Cells Combined With Solantinib Neoadjuvant Therapy in HRD+ Advanced Epithelial Ovarian Cancer: a Single-arm, Single-center, Exploratory Clinical Study

NCT06884345 is registered in ClinicalTrials.gov with Anhui Provincial Cancer Hospital as lead sponsor.

NCT NCT06884345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06884345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of METR-NK Cells Combined With Solantinib Neoadjuvant Therapy in HRD+ Advanced Epithelial Ovarian Cancer: a Single-arm, Single-center, Exploratory Clinical Study
Lead sponsor
Anhui Provincial Cancer Hospital
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 13, 2025
Completion date
December 31, 2028
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer